| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Operating Officer | EVP, General Counsel | SVP, General Counsel
2 companies
David T Howton is Chief Operating Officer at SLDB, with reported holdings spanning 2 companies. David T Howton's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $1.3M at current prices.
Our model assigns David T Howton a below-average insider score of 34/100, based on 7 past trades. Over a 12-month horizon, none of those trades were profitable, with an average 12-month return of -34.8%.
David T Howton's largest disclosed position is in SLDB as Chief Operating Officer, worth about $660K. The SLDB filings lean toward selling, a net 85,066 shares.
David T Howton has 34 Form 4 filings on record from February 2015 to February 2026, across 2 companies: Chief Operating Officer at Solid Biosciences (SLDB), 2022–2026; EVP, General Counsel at Sarepta Therapeutics (SRPT), 2015–2020.
The 99 reported transactions were 38 option exercises, 24 open-market sales, 21 option or other derivative awards and 10 tax withholdings, plus smaller numbers of other types.
Counted by filing, the open-market trades come to no purchases and 15 sales worth about $43.8M.
The largest open-market sale was 105,122 shares of SRPT at an average $170.88 on June 22, 2020, about $18.0M.
5 of the 7 sales since April 2023 were made under a Rule 10b5-1 trading plan; the other 2 were not.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Feb 18, 2026 | SLDB Solid Biosciences Inc. | Chief Operating Officer | Sale+OE10b5-1 | 7,469 | $5.82 | $43,494.23 | -6.6% | +2.7% | - | |
| Feb 4, 2026 | SLDB Solid Biosciences Inc. | Chief Operating Officer | Sell10b5-1 | 18,894 | $6.44 | $121,713.26 | -16.2% | +5.8% | - | |
| Feb 2, 2026 | SLDB Solid Biosciences Inc. | Chief Operating Officer | Sale+OE10b5-1 | 37,771 | $6.44 | $243,128.15 | -24.4% | +12.4% | - | |
| Dec 3, 2025 | SLDB Solid Biosciences Inc. | Chief Operating Officer | Sale+OE10b5-1 | 4,932 | $5.11 | $25,202.52 | -13.0% | +15.0% | - | |
| Feb 14, 2025 | SLDB Solid Biosciences Inc. | Chief Operating Officer | Sale+OE10b5-1 | 5,561 | $3.96 | $22,021.56 | -18.3% | -35.7% | +53.6% | |
| Dec 3, 2024 | SLDB Solid Biosciences Inc. | Chief Operating Officer | Sale+OE | 5,072 | $5.60 | $28,396.10 | -24.5% | -1.2% | +0.2% | |
| Dec 4, 2023 | SLDB Solid Biosciences Inc. | Chief Operating Officer | Sale+OE | 5,367 | $2.78 | $14,920.26 | -41.1% | +181.7% | +50.6% | |
| Jun 22, 2020 | SRPT Sarepta Therapeutics, Inc. | EVP, General Counsel | Sale+OE | 105,122 | $170.88 | $17,962,831.28 | -76.7% | - | - | |
| Dec 13, 2019 | SRPT Sarepta Therapeutics, Inc. | EVP, General Counsel | Sale+OE | 78,000 | $125.50 | $9,789,000.00 | -75.6% | - | - | |
| Nov 22, 2019 | SRPT Sarepta Therapeutics, Inc. | EVP, General Counsel | Sale+OE | 25,000 | $105.00 | $2,625,000.00 | -67.6% | - | - |